sscart-19 cells
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2021 (NCT04825496)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06987916 | Phase 1/Phase 2 (Phase 2) | Apr 22, 2025 | Huazhong University of Science and Technology |
| NCT07093073 | Phase 1 | Jan 23, 2025 | Huazhong University of Science and Technology, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
| NCT06367114 | Phase 2 | Apr 30, 2024 | Peking University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, Soochow University |
| NCT04825496 | Phase 1 | Apr 25, 2021 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, Soochow University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | For profit | 3 | 3 | 2 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 1 | 2 | 2025 |
| Soochow University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1